Using Genetics to Identify Hereditary Colorectal Polyposis and Cancer Syndromes in Your Patient

Current Gastroenterology Reports

Volumn 17, Issue 10, 2015, Pages

  Macaron, Carole ^a   Heald, Brandie ^b   Burke, Carol A ^b  

^a DEPARTMENT OF VETERANS AFFAIRS   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Colorectal cancer; Colorectal polyps; Genetics; Hereditary colorectal cancer syndromes; Lynch syndrome

Indexed keywords

AGE; CLINICAL FEATURE; COLON POLYP; COLON POLYPOSIS; COLORECTAL CANCER; COLORECTAL TUMOR; ENVIRONMENTAL FACTOR; FAMILIAL COLON POLYPOSIS; FAMILIAL COLORECTAL CANCER TYPE X; GENETIC ANALYSIS; GENETIC COUNSELING; GENETIC SCREENING; GENETIC TRAIT; GENOTYPE ENVIRONMENT INTERACTION; GERMLINE MUTATION; HEREDITARY ADENOMATOUS POLYPOSIS SYNDROME; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER SYNDROME; HUMAN; JUVENILE POLYPOSIS SYNDROME; LIFESTYLE; LYNCH LIKE SYNDROME; MUTATIONAL ANALYSIS; MUTYH ASSOCIATED POLYPOSIS; NEXT GENERATION SEQUENCING; PEUTZ JEGHERS SYNDROME; POLYMERASE PROOFREADING ASSOCIATED POLYPOSIS; PTEN HAMARTOMA TUMOR SYNDROME; REVIEW; SANGER SEQUENCING; SEQUENCE ANALYSIS; ADENOMATOUS POLYPOSIS COLI; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; GENETIC PREDISPOSITION; GENETICS; PEUTZ-JEGHERS SYNDROME; PROCEDURES;

ADENOMATOUS POLYPOSIS COLI; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; GENETIC COUNSELING; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; GERM-LINE MUTATION; HUMANS; PEUTZ-JEGHERS SYNDROME;

EID: 84939606409     PISSN: 15228037     EISSN: 1534312X     Source Type: Journal    
DOI: 10.1007/s11894-015-0463-z     Document Type: Review

References (40)

1. Vasen HF, Mecklin JP, Khan PM, et al. The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). Dis Colon Rectum. 1991;34:424–5.
2. Vasen HF, Watson P, Mecklin JP, et al. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology. 1999;116:1453–6.
3. Syngal S, Fox EA, Eng C, et al. Sensitivity and specificity of clinical criteria for hereditary non-polyposis colorectal cancer associated mutations in MSH2 and MLH1. J Med Genet. 2000;37:641–5.
4. Hampel H, Frankel WL, Martin E, et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med. 2005;352:1851–60.
5. Macaron C, Leach BH, Burke CA. Hereditary colorectal cancer syndromes and genetic testing. J Surg Oncol. 2015;111(1):103–11.
6. Giardiello FM, Allen JI, Axilbund JE, et al. Guidelines on genetic evaluation and management of lynch syndrome: a consensus statement by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2014;147:502–26. This paper is the latest United States consensus statement on the management of individuals with Lynch syndrome.
7. Yurgelun MB, Goel A, Hornick JL, et al. Microsatellite instability and DNA mismatch repair protein deficiency in Lynch syndrome colorectal polyps. Cancer Prev Res. 2012;5(4):574–82. This paper demonstrates the accuracy of MSI and IHC analysis obtained at endoscopic resection/biopsy of adenomatous polyps in patients with Lynch syndrome.
8. Evaluation of Genomic Applications in Practice and Prevention. Recommendation from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genet Med 2009 Jane;11(1):35–41.
9. Rodriguez-Soler M, Perez-Carbonell L, Guarinos C, et al. Risk of cancer in cases of suspected lynch syndrome without germline mutation. Gastroenterology. 2013;144:926–32.
10. Mensenkamp AR, Vogelaar IP, van Zelst-Stams WA, et al. Somatic mutations in MLH1 and MSH2 are a frequent cause of mismatch-repair deficiency in Lynch syndrome-like tumors. Gastroenterology. 2014;146:643–6. Landmark article demonstrating the occurrence and prevalence of bi-allelic somatic mutations in patients with Lynch like syndrome.
11. Lindor NM, Rabe K, Petersen GM, et al. Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency: familial colorectal cancer type X. JAMA. 2005;293:1979–85. Important paper demonstrating the lower risk of CRC and negative risk of extra-colonic cancers in patients who meet Amsterdam criteria but no evidence of MMR deficiency in their tumors.
12. Bonadona V, Bonaïti B, Olschwang S, et al. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA. 2011;305(22):2304–10.
13. Hendriks YM, Wagner A, Morreau H, et al. Cancer risk in hereditary nonpolyposis colorectal cancer due to MSH6 mutations: impact on counseling and surveillance. Gastroenterology. 2004;127:17–25.
14. Senter L, Clendenning M, Sotamaa K, et al. The clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations. Gastroenterology. 2008;135(2):419–28.
15. Edelstein DL, Axilbund J, Baxter M, et al. Rapid development of colorectal neoplasia in patients with Lynch syndrome. Clin Gastroenterol Hepatol. 2011;9(4):340–3.
16. Syngal S, Brand RE, Church JM, et al. ACG Clinical Guideline: genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol. 2015;110:223–62. Latest United States consensus statement on genetic testing and management of hereditary gastrointestinal cancer syndromes.
17. Vasen HF, Blanco I, Aktan-Collan K, et al. Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. Gut. 2013;62(6):812–23. Latest European guidelines on clinical management of Lynch syndrome.
18. Haanstra JF, Kleibeuker JH, Koornstra JJ. Role of new endoscopic techniques in Lynch syndrome. Familial Cancer. 2013;12(2):267–72.
19. Kamiński MF, Hassan C, Bisschops R, et al. Advanced imaging for detection and differentiation of colorectal neoplasia: European Society of Gastrointestinal Endoscopy (ESGE) guideline. Endoscopy. 2014;46:435–49.
20. Bianchi L, Burke CA, Bennett A, et al. Fundic gland polyp dysplasia is common in familial adenomatous polyposis. Clin Gastroenterol Hepatol. 2008;6:180–5.
21. Jarrar AM, Milas M, Mitchell J, et al. Screening for thyroid cancer in patients with familial adenomatous polyposis. Ann Surg. 2011;253:515–21.
22. Feng X, Milas M, O'Malley M, et al. Characteristics of benign and malignant thyroid disease in familial adenomatous polyposis patients and recommendations for disease surveillance. Thyroid. 2015;25(3):325–32.
23. Tenesa A, Campbell H, Barneston R, et al. Association of MUTYH and colorectal cancer. Br J Cancer. 2006;95:239–42.
24. Theodoratou E, Campbell H, Tenesa A, et al. A large-scale meta-analysis to refine colorectal cancer risk estimates associated with MUTYH variants. Br J Cancer. 2010;103:1875–84.
25. Win AK, Dowty JG, Cleary SP, et al. Risk of colorectal cancer for carriers of mutations in MUTYH with or without a family history of cancer. Gastroenterology. 2014;146:1208–11.
26. Palles C, Cazier JB, Howarth KM, et al. Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas. Nat Genet. 2013;45:136–44.
27. NCCN Clinical Practice Guidelines in Oncology. Genetic/familial high-risk assessment: colorectal. Version I.2015. NCCN.org
28. Aytac E, Sulu B, Heald B, et al. Genotype-defined cancer risk in juvenile polyposis syndrome. Br J Surg. 2015;102(1):114–8.
29. O’Malley M, LaGuardia L, Kalady MF, et al. The prevalence of hereditary hemorrhagic telangiectasia in juvenile polyposis syndrome. Dis Colon Rectum. 2012;55:886–92.
30. Giardello FM, Brensinger JD, Tersmette A, et al. Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology. 2000;119:1447–53.
31. Heald B, Mester J, Rybicki L, et al. Frequent gastrointestinal polyps and colorectal adenocarcinomas in a prospective series of PTEN mutation carriers. Gastroenterology. 2010;139:1927–33.
32. Mester J, Eng C. When overgrowth bumps into cancer: the PTEN-opathies. Am J Med Genet C: Semin Med Genet. 2013;163C:114–21.
33. Heald B, Church J. Genetic testing for hereditary colorectal cancer syndromes: a significant change in technology and its clinical implications. Color Dis. 2014;16(12):942–6.
34. Meder B, Haas J, Keller A, et al. Targeted next-generation sequencing for the molecular genetic diagnostics of cardiomyopathies. Circ Cardiovasc Genet. 2011;4(2):110–22.
35. Pritchard CC, Smith C, Salipante SJ, et al. ColoSeq provides comprehensive lynch and polyposis syndrome mutational analysis using massively parallel sequencing. J Mol Diagn. 2012;14(4):357–66.
36. Morgan JE, Carr IM, Sheridan E, et al. Genetic diagnosis of familial breast cancer using clonal sequencing. Hum Mutat. 2010;31(4):484–91.
37. Hall MJ, Forman AD, Pilarski R, Wiesner G, Giri VN. Gene panel testing for inherited cancer risk. J Natl Compr Cancer Netw. 2014;12(9):1339–46.
38. Mauer CB, Pirzadeh-Miller SM, Robinson LD, Euhus DM. The integration of next-generation sequencing panels in the clinical cancer genetics practice: an institutional experience. Genet Med 2013.
39. Kurian AW, Hare EE, Mills MA, et al. Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment. J Clin Oncol. 2014;32(19):2001–9.
40. Stoffel EM, Mangu PB, Gruber SB, et al. Hereditary colorectal cancer syndromes: American Society of Clinical Oncology Clinical Practice Guideline endorsement of the familial risk-colorectal cancer: European Society for Medical Oncology Clinical Practice Guidelines. J Clin Oncol. 2015;33(2):209–17. Latest consensus statement on diagnosis and management of patients with hereditary colorectal cancer.